A phase I clinical study of PF-6928316
Latest Information Update: 30 Jan 2020
At a glance
- Drugs Respiratory syncytial virus vaccine Pfizer (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Proof of concept
Most Recent Events
- 28 Jan 2020 According to a Pfizer media release, data from this study is expected in first half of 2020.
- 11 Sep 2018 New trial record